Change - Announcement of Appointment::Announcement of Appointment of Deputy Group Chief Executive Officer

Issuer & Securities

Issuer/ Manager
VICPLAS INTERNATIONAL LTD
Securities
VICPLAS INTERNATIONAL LTD - SG1G57870584 - 569
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
19-Jan-2022 07:13:10
Status
New
Announcement Sub Title
Announcement of Appointment of Deputy Group Chief Executive Officer
Announcement Reference
SG220119OTHRLTL4
Submitted By (Co./ Ind. Name)
Esther Au
Designation
Secretary
Description (Please provide a detailed description of the event in the box below)
Announcement of Appointment of Deputy Group Chief Executive Officer

Additional Details

Date Of Appointment
01/02/2022
Name Of Person
Walter Tarca
Age
65
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The appointment is part of Vicplas Group's succession plan that is focused on developing leaders who can contribute to making Vicplas a strong and successful company for all its stakeholders.

Mr Tarca has been the President of the Vicplas Medical Devices segment (Forefront Medical) since 2016 and has demonstrated excellent leadership in transforming the Medical Devices segment into the major contributor to the Vicplas Group. He will continue to work under the leadership of Mr Cheng Liang, the Group Chief Executive Officer of the Vicplas Group during a transition period and will assume the responsibility of Group Chief Executive Officer of the Vicplas Group from the start of the next financial year beginning 1 August 2022 ("CEO Succession"). After the transition Mr Tarca will also continue as President of the Medical Devices segment.

The Nominating Committee has recommended and the Board has approved Mr Tarca's appointment as Deputy Group Chief Executive Officer of the Vicplas Group and the CEO Succession. The NC and the Board opined that Mr Tarca is a focused and driven leader with a deep understanding of the Vicplas businesses and the needs of Vicplas customers, employees and other stakeholders, and he is fully committed to continuing to drive sustainable long term growth for the Vicplas Group.
Whether appointment is executive, and if so, the area of responsibility
Executive and the overall management of the Group
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Deputy Group Chief Executive Officer
Professional qualifications
Bachelor of Economics, University of Adelaide
Fellow, CPA Australia
Fellow, Australian Institute of Company Directors
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Mr Tarca's son is employed as a senior customer service executive with Forefront Medical Investment Pte Ltd, a wholly owned subsidiary of Vicplas, and his son does not hold a managerial position.
Conflict of interests (including any competing business)
None
Working experience and occupation(s) during the past 10 years
Forefront Medical, Singapore (Medical Devices Contract Manufacturer) as President from January 2016 to current, based in Singapore.

Elekta Corporation, Swedish MNC (Manufacturer of Radiotherapy equipment used in the treatment of cancer) as Vice President Operations & Finance Asia Pacific from 2014 to 2016, based in Hong Kong.

Nucletron Corporation, Netherlands MNC (Manufacturer of Radiotherapy equipment used in treatment of cancer) as Vice President Asia Pacific from 2010 to 2014, based in Hong Kong.

Tyco Healthcare, U.S.A. MNC (Product owner and manufacturer of Medical Devices) as President Asia Pacific from 2004 to 2009, based in Singapore.
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Direct interest - 510,000 ordinary shares
Direct interest - 9,490,000 options
Other Principal Commitments* Including Directorships#
*"Principal Commitments" has the same meaning as defined in the Code
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
None
Present
XentiQ (Pte.) Ltd.
Arrow Medical Limited
Arrow Medical Products Limited
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of Director only.
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
N.A.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N.A.